MHRA's August Advertising Report Lands as a New Weight-Loss Pill Hits the Market

The MHRA's monthly "Advertising investigations" bulletin, its record of decisions against adverts found to breach the Human Medicines Regulations 2012, is the agency's main public account of how it polices promotion of prescription-only medicines. The August 2026 edition typically covers cases from the prior month, and recent editions have been dominated by one category: weight-loss drugs.

That focus has intensified since 10 August 2026, when the MHRA approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, the first such approval in Europe. It is available privately, priced to undercut Mounjaro's roughly £399-a-month cost, while NHS access awaits a National Institute for Health and Care Excellence review. A drug cheaper and easier to take than existing injectables creates an obvious incentive to advertise it to the public before licensing catches up, which is precisely what the Human Medicines Regulations forbid for prescription-only medicines.

The MHRA had already flagged this risk. On 18 June 2026, it issued a joint statement with the General Pharmaceutical Council and the Advertising Standards Authority reminding pharmacies and manufacturers that unlicensed or pipeline weight-loss products cannot be promoted to consumers, a warning issued roughly a week after oral semaglutide's approval. The July 2026 report, published 5 August, showed the warning had limited bite: Medex Pharmaceuticals, Bishops Waltham Pharmacy, Simple Online Pharmacy and Cured Pharmacy all amended ads only after MHRA complaints.

The GPhC has quantified the pattern separately, finding that 17% of all pharmacy-conduct concerns raised between January 2024 and December 2025 involved weight-loss advertising or services. Whether Foundayo's launch produces fresh named cases in the August report, due in early September, will show if repeated warnings change behavior before regulators have to intervene again.